Effect of Compound Glycyrrhizin Injection on liver function and cellular immunity of children with infectious mononucleosis complicated liver impairment
- 62 Downloads
To investigate the effects of Compound Glycyrrhizin Injection (CGI) on liver function and cellular immunity of children with infectious mononucleosis complicated liver impairment (IM-LI) and to explore its clinical therapeutic effect.
Forty-two patients with IM-LI were randomly assigned, according to the randomizing number table, to two groups, 20 in the control group and 22 in the treated group. All the patients were treated with conventional treatment, but to those in the treated group, CGI was given additionally once a day, at the dosage of 10 ml for children aged below 2 years, 20 ml for 2–4 years old, 30 ml for 5–7 years old and 40 ml for 8–12 years old, in 100–200 ml of 5% glucose solution by intravenous dripping. The treatment lasted for 2 weeks. T lymphocyte subsets and serum levels of alanine transaminase (ALT), aspartate aminotransferase (AST) and total bilirubin (TBil) were detected before and after treatment. Besides, a normal control group consisting of 20 healthy children was also set up.
Baseline of the percentage of CD3 +, CD8 + lymphocyte and serum levels of ALT, AST, TBiL in the children with IM-LI were markedly higher, while the percentage of CD4 + lymphocyte and the CD4 +/CD8 + ratio was markedly lower in IM-LI children as compared with the corresponding indices in the healthy children (P<0.01). These indices were improved after treatment in both groups of patients, but the improvement in the treated group was better than that in the control group (P<0.01).
Cellular immunity dysfunction often occurs in patients with IM-LI, and CGI treatment can not only obviously promote the recovery of liver function, but also regulate the immune function in organism.
Key Wordsinfectious mononucleosis liver impairment T lymphocyte subsets Compound Glycyrrhizin Injection treatment
Unable to display preview. Download preview PDF.
- 1.Tan ZY, Yu MX, Fu CJ, et al. Diagnosis of infectious mononucleosis in children. Guangdong Med J 2000;21(1): 45–46.Google Scholar
- 2.Chen H, Yang JJ. A study on the change of immunity in children with infectious mononucleosis. J Clin Res 2005;22(5): 600–601.Google Scholar
- 3.Yu SC, Zhu LF, Shi XP, et al. Dynamic observation of the immunity function of the children with infectious mononucleosis. Modern Prevent Med 2004;31(4): 527–528.Google Scholar
- 4.Hu YM, Jiang ZF, editors. Practical pediatrics. 7th ed. Beijing: People’s Medical Publishing House, 2002: 824.Google Scholar
- 5.Zhang ZN, editor. Diagnosis and therapeutic criteria of hemorrheology. Beijing: Science Press, 1998: 252–258.Google Scholar
- 6.Yang XQ, Yi ZW, editors. Pediatrics. 6th ed. Beijing: People’s Medical Publishing House, 2004: 223–226.Google Scholar
- 7.Jia QR, Zhang HY, Li XF, editors. Leukocytic disease. Beijing: Science-technology Literature Publishing House, 2002: 277.Google Scholar
- 8.Zhou YF, Jiang LR, Wang W, et al. Study on the dynamic changes of T lymphocyte subsets in children with infectious mononucleosis and infectious mononucleosis-like syndrome. J Clin Pediatr 2003;21(8): 458–460.Google Scholar
- 9.Wang XL. Epstein-Barr virus infection and related diseases. Foreign Med Sci (Sect Pediatr) 2005;32(5): 287–290.Google Scholar
- 11.Song FW, Li XJ, Jiang YS. Changes of liver pathology with stronger neo-minophagen (SNMC). Chin J Modern Med 2001;11(11): 24–27.Google Scholar
- 12.Weng CH, Lin MX, Yang YF. et al. The clinical analysis of infectious mononucleosis with hepatic lesion. Hebei Med 2005;11(6): 558–560.Google Scholar